Immix... recnac latceroloc ni 011-XMI r

Immix Biopharma (NASDAQ:IMMX) reported early interim data from a phase 1b/2a trial of IMX-110 in combination with Novartis (NYSE:NVS) and BeiGene's (NASDAQ:BGNE) tislelizumab to treat patients with ad... Stay informed with the latest.
People & Interviews
上一篇:Extraordinary... sseccus etarbelec ot pirt ilaB
下一篇:Ethereum... sessoL suoiverP dimA tiforP no